Home
Licensing

Work Area: Licensing

Via Licensing taps Xiaomi’s former IP strategy head as advisor

Paul Lin, now managing director of Eagle Forest, aims to provide the licensee’s perspective to arm Via as it navigates a shifting patent pool landscape

InterDigital’s UK setback highlights patent litigation risks

In retrospect, the US R&D and licensing business would surely have preferred to take a hit in order to settle its dispute with Lenovo out of sight and in secret

WiLAN boosts 2022 licensing revenue 470% YOY thanks to big licences to Apple, others

Parent company Quarterhill is still undergoing a strategic review to determine whether to sell WiLAN, but doesn’t want the delay to remind anyone of the stagnant BlackBerry patent sale

Latest content

Five key patent transactions takeaways

An over-arching theme during an IAM event was the key importance of relationships, trust and empathy between parties when deals are getting done

11 November 2022

Auto SEP owners could see licensing fees shrink in China if new guidelines are enforced

Document which seeks to change rules to ‘license to all’ approach arms implementors with potential bargaining chip

11 November 2022

WiLAN revenues plummet in Q3 on prior year but Micron deal excluded

Strategic review of the licensing business nears a year in motion with no news on potential divestment announced

10 November 2022

“A strong IP and IA portfolio is the bedrock of our company”: Vivo Surgical founder on building an award-winning medtech offering

Head of Singapore-based startup reflects on the importance of patents in ensuring its products are proprietary and unique

10 November 2022

Breaking: Sisvel launches cellular IoT patent pool with 20 licensors

Licensing programme aims to boost uptake of Internet of Things cellular standards

09 November 2022

With handset sales diving, Qualcomm emphasises new licensing markets

For businesses that grew fat on the back of mobile phones, diversification into areas such as IoT and auto is now the name of the game

04 November 2022

Drug royalty agreements can help Big Pharma overcome patent cliffs, says top dealmaker

Behzad Khosrowshahi, CEO of DRI Healthcare Trust, looks at recent deals the firm has done, explains what makes a transaction attractive and how to get one over the line

04 November 2022